Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Mikhailidis
D P
DP
Jagroon
I A
IA
D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058607:Fibric Acids; D015248:Gemfibrozil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006954:Hyperlipoproteinemia Type V / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D002995:Clofibric Acid; C019304:ciprofibrate; D015248:Gemfibrozil